Illumina

YTD

ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R.

CEO

Jacob Thaysen

CEOJacob Thaysen

Employees

8,600

Employees8,600

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

8,600

Employees8,600

ILMN Key Statistics

Market cap

29.79B

Market cap29.79B

Price-Earnings ratio

34.53

Price-Earnings ratio34.53

Dividend yield

—

Dividend yield—

Average volume

1.46M

Average volume1.46M

High today

$191.96

High today$191.96

Low today

$191.96

Low today$191.96

Open price

$190.00

Open price$190.00

Volume

1.23K

Volume1.23K

52 Week high

$196.66

52 Week high$196.66

52 Week low

$88.00

52 Week low$88.00

Stock Snapshot

Illumina(ILMN) stock is priced at $191.96, giving the company a market capitalization of 29.79B. It carries a P/E multiple of 34.53.

During the trading session on 2026-07-23, Illumina(ILMN) shares reached a daily high of $191.96 and a low of $191.96. At a current price of $191.96, the stock is 0.0% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 1.23K, compared to an average daily volume of 1.46M.

Over the past 52 weeks, Illumina(ILMN) stock has traded between a high of $196.66 and a low of $88.00.

ILMN News

Simply Wall St 16h

Illumina Faces A German Recall Order, Is The Stock Fully Priced?

A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, pla...

Simply Wall St 2d

The Bull Case For Eli Lilly Could Change Following Its Deeper Role In Illumina’s Billion Cell Atlas

In January 2026, Illumina announced the launch of its Billion Cell Atlas alliance, naming Eli Lilly as a founding member in a program that uses CRISPR-based, la...

TipRanks 6d

Illumina price target raised to $210 from $175 at Leerink

Leerink analyst Puneet Souda raised the firm’s price target on Illumina (ILMN) to $210 from $175 and keeps an Outperform rating on the shares. The firm cites hi...

Analyst ratings

52%

of 23 ratings

Buy

52.2%

Hold

26.1%

Sell

21.7%

More ILMN News

Simply Wall St 7d

Illumina Expands Billion Cell Atlas Alliance With New AI Drug Discovery Members

Illumina expanded its Billion Cell Atlas alliance with three new members, including AI-first drug developer Formation Bio. The alliance aims to build and share...

TipRanks 7d

Illumina adds three new member companies to Billion Cell Atlas alliance

Illumina (ILMN) announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. “As leade...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.